Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added to standard care in patients with moderate-to-severe lupus.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.

Biomacromolecules are increasingly important for treating major diseases such as tumors, infections, cardiovascular diseases, metabolic disorders, ...

AstraZeneca (NASDAQ:AZN) is one of the best future stocks to buy for the long term. On January 6, Barclays analyst James Gordon raised the firm’s price target on AstraZeneca to 16,500 GBp from 14,000 ...